Vertex Pharmaceuticals (VRTX) 44th Annual J.P. Morgan Healthcare Conference summary

Corporate strategy, R&D, and financial outlook

• Focuses on transformative medicines for serious diseases with high unmet need, targeting specialty markets and reinvesting in R&D, with majority of OpEx allocated to innovation.

• Pipeline spans over 10 disease areas, with five launches targeted by 2028 and a goal of five launches in five disease areas over five years.

• Emphasizes commercial diversification with established franchises in CF, hematology, acute pain, and an emerging renal vertical.

• 2025 revenue guidance at $11.9–$12 billion, with strong cash flow, $12B cash on hand, and $1.9B deployed in share repurchases through Q3 2025.

• Two-thirds of OpEx targeted to innovation, maintaining strong operating margins and a healthy balance sheet.

Cystic fibrosis (CF) franchise and pipeline

• Five to seven globally commercialized CF medicines, with patent protection through ~2040 and access in over 60 countries.

• Over 200,000 patient-years of real-world data; 95% of patients eligible for CFTR modulators; global CF penetration at 73-74%.

• ALYFTREK launch and expansion to younger patients expected to drive majority of eligible patients to switch from TRIKAFTA; ongoing submissions for younger age groups.

• Next-generation assets (VX-522, VX-828) for patients not benefiting from current modulators, with Phase 1/2 and H2 2026 data readouts.

• ~3% annual CF population growth and high patient adherence support sustained revenue.

Hematology and gene therapy: Casgevy

• Casgevy positioned for blockbuster status, exceeded $100M revenue in FY 2025, and targets multi-billion-dollar potential in sickle cell and beta thalassemia.

• Broad U.S. coverage (~90% Medicaid & commercial) and access in 12+ countries, with expansion to younger patients planned.

• Projected >90% reduction in lifetime vaso-occlusive crises and transfusions for SCD and TDT patients.

• Manufacturing and CMC processes are consistent and high quality, with ongoing improvements to conditioning regimens.